Author(s):
Sudhakar Kothandan, Gowthamarajan K
Email(s):
sudhagar2730@gmail.com , gowthamsang@jssuni.edu.in
DOI:
10.52711/2231-5659.2024.00057 
Address:
Sudhakar Kothandan, Gowthamarajan K
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 4,
Year - 2024
ABSTRACT:
Dry eye disease (DED) is a growing public health concern affecting the quality of life and visual function, with a significant socio-economic impact. It's characterized by a breakdown of homeostasis, which causes tear film instability, hyperosmolarity, and ocular surface inflammation. Ocular surface disorders are also clinically very important to manage especially in terms of visual acuity. With a better understanding of the pathophysiology and etiology of DE disease (DED), the disease process can be managed and treated more meticulously. In this review article described more on the diagnostic tests, medical and surgical management, and future trends of DED.
Cite this article:
Sudhakar Kothandan, Gowthamarajan K. A Review of Recent Diagnostic Methods and Advanced Treatments for Dry Eye Syndrom. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(4):359-6. doi: 10.52711/2231-5659.2024.00057
Cite(Electronic):
Sudhakar Kothandan, Gowthamarajan K. A Review of Recent Diagnostic Methods and Advanced Treatments for Dry Eye Syndrom. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(4):359-6. doi: 10.52711/2231-5659.2024.00057 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2024-14-4-5
REFERENCES:
1. Li M, Gong L, Sun X, et al. Anxiety and depression in patients with dry eye syndrome. Current Eye Research. 2011; 36(1): 1-7.
2. Szczesna DH, Alonso-Caneiro D, Iskander DR, et al. Predicting dry eye using noninvasive techniques of tear film surface assessment. Investigative Ophthalmology and Visual Science. 2011; 52(2): 751-6.
3. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. American Journal of Ophthalmology. 2011; 151(5): 792-8.
4. Veres A, Tapasztó B, Kosina-Hagyó K, et al. Imaging lid-parallel conjunctival folds with OCT and comparing its grading with the slit lamp classification in dry eye patients and normal subjects. Investigative Ophthalmology and Visual Science. 2011; 52(6): 2945-51.
5. Sendecka M, Baryluk A, Polz-Dacewicz M. Prevalence and risk factors of dry eye syndrome. Przeglad Epidemiologiczny. 2004; 58(1): 227-33.
6. Su MY, Perry HD, Barsam A, et al. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy. Cornea. 2011; 30(10):1098-104.
7. McGinnigle S, Naroo SA, Eperjesi F. Evaluation of dry eye. Survey of Ophthalmology. 2012; 57(4):293-316.
8. Varikooty J, Keir N, Simpson T. Estimating tear film spread and stability through tear hydrodynamics. Optometry and Vision Science. 2012; 89(8): E1119-24.
9. Nguyen P, Huang D, Li Y, Sadda SR, et al. Correlation between optical coherence tomography-derived assessments of lower tear meniscus parameters and clinical features of dry eye disease. Cornea. 2012; 31(6): 680.
10. Chung YW, Oh TH, Chung SK. The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean Journal of Ophthalmology. 2013; 27(3): 167-71.
11. Akpek EK, Amescua G, Farid M, et al. Dry eye syndrome preferred practice pattern®. Ophthalmology. 2019; 126(1): P286-334.
12. Vitali C, Bootsma H, Bowman SJ, et al. Classification criteria for Sjögren's syndrome: we actually need to definitively resolve the long debate on the issue. Annals of the Rheumatic Diseases. 2013; 72(4): 476-8.
13. Finis D, Pischel N, Schrader S, et al. Evaluation of lipid layer thickness measurement of the tear film as a diagnostic tool for Meibomian gland dysfunction. Cornea. 2013; 32(12): 1549-53.
14. Lin H, Yiu SC. Dry eye disease: A review of diagnostic approaches and treatments. Saudi Journal of Ophthalmology. 2014; Jul 1; 28(3): 173-81.
15. Uchino M, Uchino Y, Dogru M, et al. Dry eye disease and work productivity loss in visual display users: the Osaka study. American Journal of Ophthalmology. 2014; 157(2): 294-300.
16. Zhang W, Wang Y, Lee BT, et al. A novel nanoscale-dispersed eye ointment for the treatment of dry eye disease. Nanotechnology. 2014; 25(12): 125101.
17. Grubbs Jr JR, Tolleson-Rinehart S, Huynh K, et al. A review of quality of life measures in dry eye questionnaires. Cornea. 2014; 33(2): 215.
18. Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. American Journal of Ophthalmology. 2014; 157(4): 799-806.
19. Prabha JL. Tear secretion-a short review. Journal of Pharmaceutical Sciences and Research. 2014; 6(3): 155.
20. Kanellopoulos AJ, Asimellis G. In vivo 3-dimensional corneal epithelial thickness mapping as an indicator of dry eye: preliminary clinical assessment. American Journal of Ophthalmology. 2014; 157(1): 63-8.
21. Williamson JF, Huynh K, Weaver MA, et al. Perceptions of dry eye disease management in current clinical practice. Eye and Contact Lens. 2014; 40(2): 111.
22. Vickers LA, Gupta PK. The future of dry eye treatment: a glance into the therapeutic pipeline. Ophthalmology and Therapy. 2015; 4: 69-78.
23. Herz JM, Kesicki EA, inventors; ALGOMEDIX Inc, assignee. Trpa1 antagonists for treatment of dry eye, ocular pain and inflammation. United States Patent Application US 16/315,113. 2020 Jun 11.
24. Vandermeer G, Chamy Y, Pisella PJ. Comparison of objective optical quality measured by double-pass aberrometry in patients with moderate dry eye: Normal saline vs. artificial tears: A pilot study. Journal Francais D'ophtalmologie. 2018; 41(2): e51-7.
25. Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. British Journal of Ophthalmology. 2019; 103(1): 125-31.
26. Aragona P, Giannaccare G, Mencucci R, et al. Modern approach to the treatment of dry eye, a complex multifactorial disease: a PICASSO board review. British Journal of Ophthalmology. 2021; 105(4): 446-53.
27. Singh S, Sharma S, Basu S. Rabbit models of dry eye disease: Current understanding and unmet needs for translational research. Experimental Eye Research. 2021; 206: 108538.
28. Downie LE, Hom MM, Berdy GJ, et al. An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial. The Ocular Surface. 2020; 18(1): 148-57.
29. Wolkoff P. Dry eye symptoms in offices and deteriorated work performance–A perspective. Building and Environment. 2020; 172: 106704.
30. Bayer IS. Hyaluronic acid and controlled release: A review. Molecules. 2020; 25(11): 2649.
31. Rafiei F, Tabesh H, Farzad F. Sustained subconjunctival drug delivery systems: Current trends and future perspectives. International Ophthalmology. 2020; 40: 2385-401.
32. Shoji J, Inada N, Tomioka A, et al. Assessment of mucin-related gene alterations following treatment with rebamipide ophthalmic suspension in Sjögren’s syndrome-associated dry eyes. Plos one. 2020; 15(11): e0242617.
33. Chen X, Lee S, Zhang T, et al. Nanomolar potency aminophenyltriazine CFTR activator reverses corneal epithelial injury in a mouse model of dry eye. Journal of Ocular Pharmacology and Therapeutics. 2020; 36(3): 147-53.
34. Perez VL, Wirostko B, Korenfeld M, et al. Ophthalmic drug delivery using iontophoresis: recent clinical applications. Journal of Ocular Pharmacology and Therapeutics. 2020; 36(2): 75-87.
35. Dukovski BJ, Juretić M, Bračko D, et al. Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment. International Journal of Pharmaceutics. 2020; 576: 118979.
36. Joossen C, Baán A, Moreno-Cinos C, et al. A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation. Scientific Reports. 2020; 10(1): 17268.
37. Hu L, Hu Z, Yu Y, et al. Preparation and characterization of a pterostilbene-peptide prodrug nanomedicine for the management of dry eye. International Journal of Pharmaceutics. 2020; 588: 119683.
38. Lin HL, Wu TH, Ho HO, et al. TEMPO-oxidized sacchachitin nanofibers (TOSCNFs) combined with platelet-rich plasma (PRP) for management of dry eye syndrome. International Journal of Nanomedicine. 2020; 1721-30.
39. Maulvi FA, Patel PJ, Soni PD, et al. Novel poly (vinylpyrrolidone)-coated silicone contact lenses to improve tear volume during lens wear: in vitro and in vivo studies. ACS Omega. 2020; 5(29): 18148-54.
40. Tong L, Sun CC, Yoon KC, et al. Cyclosporine anionic and cationic ophthalmic emulsions in dry eye disease: a literature review. Ocular Immunology and Inflammation. 2021; 29(7-8): 1606-15.
41. Yellepeddi VK, Sheshala R, McMillan H, et al. Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye. Drug Discovery Today. 2015; 20(7): 884-9.
42. Zhang C, Zheng Y, Li M, et al. Carboxymethyl Cellulose‐Coated Tacrolimus Nonspherical Microcrystals for Improved Therapeutic Efficacy of Dry Eye. Macromolecular Bioscience. 2020; 20(7): 2000079.
43. Luo LJ, Nguyen DD, Lai JY. Long-acting mucoadhesive thermogels for improving topical treatments of dry eye disease. Materials Science and Engineering: C. 2020; 115: 111095.
44. Silvani L, Bedei A, De Grazia G, et al. Arabinogalactan and hyaluronic acid in ophthalmic solution: Experimental effect on xanthine oxidoreductase complex as key player in ocular inflammation (in vitro study). Experimental Eye Research. 2020; 196: 108058.
45. Rahman SN, Pawde DM, Katari O, et al. Systematic optimization, in vitro drug release, and preliminary nonclinical toxicity assessment of nonphospholipid-based topical ophthalmic emulsions containing 0.05 or 0.1% w/w cyclosporin A for dry-eye syndrome management. AAPS PharmSciTech. 2020; 21: 1-5.
46. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Deutsches Arzteblatt International. 2015; 112(5): 71.
47. Gurnani B, Kaur K, Kumar MC. Current concepts and future trends in dry eye syndrome–A review of literature. TNOA Journal of Ophthalmic Science and Research. 2021; 59(1): 38.
48. Şimşek C, Doğru M, Kojima T, et al. Current management and treatment of dry eye disease. Turkish Journal of Ophthalmology. 2018; 48(6): 309.
49. Buckley RJ. Assessment and management of dry eye disease. Eye. 2018; 32(2): 200-3.
50. Rosenberg ES, Asbell PA. Essential fatty acids in the treatment of dry eye. The Ocular Surface. 2010; 8(1): 18-28.